Revolutionising Infant Nutrition with HMO Innovations
At Nestlé’s headquarters in Vevey, Switzerland, illuma, a global leader in premium maternal and infant nutrition, has officially launched its “Human Milk Oligosaccharides (HMO) Research Traceability Journey.” This initiative marks a significant step forward in the development of advanced HMO (Human Milk Oligosaccharide) formulas that closely mimic the benefits of human milk. The event underscores illuma’s ongoing commitment to providing cutting-edge nutritional solutions for infants, particularly in key markets like China, where infant nutrition is a top priority. The journey is designed to showcase pivotal research in the first 1,000 days of life, a critical period for infant growth and development.
Illuma’s Commitment to HMO Innovation
Bringing Advanced Nutrition to China
Illuma has rapidly expanded its presence in China, launching several advanced HMO products in response to the country’s evolving regulonsumers, providing formulas that support infant immunity and overall well-being.atory landscape. Following the National Health Commission of China’s approval of two HMOs as food additives in 2023, illuma introduced its flagship products, including illuma LUXA, illuma HMO Growing-up Formula, and illuma HMO Liquid Formula. These offerings are part of illuma’s strategy to bring innovative nutrition solutions to Chinese consumers, providing formulas that support infant immunity and overall well-being.
The next-generation HMO formulas, soon to be launched, reflect illuma’s dedication to scientific excellence. By utilising global research and development expertise, illuma is able to craft formulas that are increasingly aligned with the unique composition of human milk. This innovation is expected to elevate illuma’s reputation as a leader in infant nutrition while addressing the nutritional needs of infants in China.
Pioneering HMO Research
30 Years of Breakthroughs in Infant Nutrition
Illuma, along with Nestlé, has been at the forefront of HMO research for more than three decades. Early recognition of the role HMOs play in infant development led to groundbreaking studies and innovations. To date, illuma has published over 75 scientific papers and holds more than 100 patents related to HMOs. These achievements are the result of over 55 studies, including more than 30 clinical trials that explored the multifunctional benefits of HMOs.
Thanks to these studies, illuma has been able to integrate a broad range of HMOs into its products, making them accessible to children in over 100 countries. The formulas cater to a variety of needs, from preterm infants requiring specialised nutrition to preschoolers benefiting from ongoing immune support. Illuma’s pioneering work in HMO research continues to shape the future of maternal and infant nutrition worldwide.
Next-Generation Formulas for Infant Nutrition
Meeting the Needs of Chinese Families
Illuma’s next-generation HMO formulas are designed specifically for the Chinese market, combining two approved HMOs with a blend of α-lactalbumin and MFGM (Milk Fat Globule Membrane). This carefully formulated combination offers enhanced immunity protection and mimics the natural composition of human milk, providing infants with optimal nutrition during their early years. The formula is expected to make a significant impact on the Chinese infant nutrition market by offering a solution that is both scientifically advanced and tailored to the needs of local consumers.
Investing in Infant Nutrition
Driving Research and Development for Future Generations
Illuma’s commitment to infant nutrition goes beyond product development. The brand continuously invests in research, development, and rigorous testing to ensure that its products meet the highest quality standards. Each illuma formula is the result of extensive scientific research and meticulous clinical trials, designed to offer the best possible nutritional support for infants. With the upcoming launch of its next-generation formulas, illuma is set to further solidify its position as a trusted leader in maternal and infant nutrition.
The “HMO Research Traceability Journey” also underscores illuma’s dedication to transparency and collaboration. By highlighting the scientific milestones that have led to these advanced formulas, illuma is fostering trust among consumers and healthcare professionals alike.
The Future of Infant Nutrition with Illuma
Shaping the Next Era of Maternal and Infant Health
As illuma continues to push the boundaries of infant nutrition, its focus remains on developing formulas that support healthy development during the first 1,000 days of life. With its next-generation HMO formulas set to launch in China, illuma is not only advancing scientific innovation but also making a lasting impact on the well-being of children worldwide.
